Abstract CAR-T cell therapies have shown remarkable success in hematologic malignancies; however, their efficacy in solid tumors remains limited. This is primarily due to the complex tumor microenvironment (TME), which creates immunosuppressive conditions and physical barriers that hinder CAR-T infiltration and function. Current in vitro models fail to replicate these critical parameters, limiting the ability to predict clinical performance. To address this gap, we developed a tumor-vasculature-on-chip model using the OrganoPlate platform, enabling perfusion of CAR-T cells through a functional endothelial vessel adjacent to a tumor compartment. This setup allows assessment of key processes such as extravasation, migration, and killing kinetics in a physiologically relevant context. EpCAM-positive HT-29 colorectal cancer cells and EpCAM-negative A375 melanoma cells were co-cultured with an endothelial tubule to evaluate EpCAM-targeting CAR-T cells. CAR-T cells selectively killed EpCAM-positive HT-29 cells while sparing EpCAM-negative A375 cells, demonstrating antigen-specific activity. Killing was dose-dependent, and endothelial integrity was maintained at most CAR-T concentrations but disrupted at the highest doses, revealing a therapeutic window. We further compared CAR-T constructs with different co-stimulatory domains (CD28 vs. 4-1BB) and observed reduced potency with 4-1BB. Addition of IL-2 enhanced CAR-T cytotoxicity. Cytokine profiling showed increased IFN-γ, TNF-α, and IL-6 over time, and morphometric analysis confirmed endothelial disruption at high effector-to-target ratios. The platform was also used to study combination strategies, including immune checkpoint inhibitors and temozolomide. This modular, scalable organ-on-chip system enables phenotypic and functional characterization of CAR-T cells under relevant conditions. Citation Format: Luuk de Haan, Aleksandra Olczyk, Thomas Olivier, Joris Wesselius, Will Allen, Johnny Suiker, Todd Burton, Lenie van den Broek, Karla Queiroz, . CAR-Tmigration andcytotoxicity in atumor-vasculature-on-chipmodel abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4929.
Building similarity graph...
Analyzing shared references across papers
Loading...
Luuk de Haan
Aleksandra Olczyk
Thomas Olivier
Cancer Research
Mimetas (Netherlands)
Building similarity graph...
Analyzing shared references across papers
Loading...
Haan et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69d1fd62a79560c99a0a3627 — DOI: https://doi.org/10.1158/1538-7445.am2026-4929
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: